改良Rutgeerts评分对克罗恩病初次回盲部切除术后长期结局的预后价值
本研究回顾性纳入652例克罗恩病初次回盲部切除术后有首次结肠镜改良Rutgeerts评分(mRS)的患者,评估mRS对长期结局的预后价值。中位随访6.4年(SD 4.6),随着mRS升高,手术复发、临床复发及进展至严重内镜复发的风险增加。
要点
- mRS i2b、i3、i4与手术复发相关。
- mRS≥i1与临床复发相关。
- i1或i2b与进展至严重内镜复发相关。
核心结论
- mRS升高与手术复发和临床复发风险密切相关。
- 首次术后mRS≥i2b与手术复发相关,mRS≥i1与临床复发相关,i1或i2b与进展至严重内镜复发相关。
研究设计与样本
- 回顾性纳入652例克罗恩病初次回盲部切除术后有首次术后回结肠镜mRS(指数mRS)的患者。
- 采用Cox比例风险模型评估指数mRS与结局的关联。
主要发现
- 手术复发率在指数mRS i0、i1、i2a、i2b、i3、i4分别为7.7%、5.3%、12.9%、19.1%、28.8%、47.8%。
- 临床复发率在i0、i1、i2a、i2b、i3、i4分别为42.2%、53.7%、58.5%、80.2%、79.4%、95.3%。
- 进展至严重内镜复发率在i0、i1、i2a、i2b分别为21.1%、33.9%、26.8%、33.3%。
- 指数mRS i2b(aHR 3.0;95%CI 1.5-5.6)、i3(aHR 4.0;95%CI 2.0-7.9)、i4(aHR 8.0;95%CI 4.0-16.0)与手术复发相关。
- 指数mRS i1(aHR 1.7;95%CI 1.2-2.4)、i2a(aHR 1.7;95%CI 1.2-2.4)、i2b(aHR 4.4;95%CI 3.2-6.0)、i3(aHR 3.6;95%CI 2.5-5.2)、i4(aHR 7.3;95%CI 4.8-10.9)与临床复发相关。
临床怎么用
- 作者认为,这些结果支持对存在回肠病变的患者密切监测疾病活动并优化治疗,对吻合口病变患者采取更保守的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prognostic value of the modified Rutgeerts score (mRS) in patients with Crohn's disease (CD) needs to be further elucidated. This study assessed the prognostic value of the mRS for long-term outcomes after primary ileocecal resection in patients with CD. METHODS: Patients with CD after primary ileocecal resection with an available mRS at first postoperative ileocolonoscopy (index mRS) were retrospectively included. The primary outcome was surgical recurrence. Secondary outcomes were clinical recurrence and progression to severe endoscopic recurrence (≥i3). Cox proportional hazard models were used to assess the association between index mRS and outcomes. RESULTS: Six hundred fifty-two patients were included (mean follow-up: 6.4 years, SD: 4.6). Surgical recurrence rates were 7.7%, 5.3%, 12.9%, 19.1%, 28.8%, 47.8% for index mRS i0, i1, i2a, i2b, i3, and i4, respectively. Clinical recurrence occurred in 42.2% (i0), 53.7% (i1), 58.5% (i2a), 80.2% (i2b), 79.4% (i3), and 95.3% (i4) of patients. Progression to severe endoscopic recurrence occurred in 21.1% (i0), 33.9% (i1), 26.8% (i2a), and 33.3% (i2b) of patients. An index mRS of i2b (adjusted hazard ratio [aHR] 3.0; 1.5-5.6), i3 (aHR 4.0; 2.0-7.9) and i4 (aHR 8.0; 4.0-16.0) were associated with surgical recurrence. An index mRS of i1 (aHR 1.7; 1.2-2.4), i2a (aHR 1.7; 1.2-2.4), i2b (aHR 4.4; 3.2-6.0), i3 (aHR 3.6; 2.5-5.2), and i4 (aHR 7.3; 4.8-10.9) were associated with clinical recurrence. An index mRS of i1 (aHR 2.0; 1.1-3.7) or i2b (aHR 2.5; 1.4-4.6) was associated with progression to severe endoscopic recurrence. DISCUSSION: The increasing mRS corresponds closely with the risk of surgical and clinical recurrence. An index mRS ≥ i2b is associated with surgical recurrence, an index mRS ≥ i1 is associated with clinical recurrence, and i1 or i2b with progression to severe endoscopic recurrence. These results support tight monitoring of disease activity and treatment optimization in patients with ileal lesions and a more conservative management in patients with anastomotic lesions.
引用
- Bak MTJ, Ten Bokkel Huinink S, Erler NS, et al. Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease. Am J Gastroenterol. 2023. PMID: 37737675. doi:10.14309/ajg.0000000000002509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。